Nicholas D. James

34.0k total citations · 3 hit papers
344 papers, 13.6k citations indexed

About

Nicholas D. James is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Nicholas D. James has authored 344 papers receiving a total of 13.6k indexed citations (citations by other indexed papers that have themselves been cited), including 188 papers in Pulmonary and Respiratory Medicine, 125 papers in Surgery and 123 papers in Oncology. Recurrent topics in Nicholas D. James's work include Prostate Cancer Treatment and Research (137 papers), Bladder and Urothelial Cancer Treatments (111 papers) and Urinary and Genital Oncology Studies (61 papers). Nicholas D. James is often cited by papers focused on Prostate Cancer Treatment and Research (137 papers), Bladder and Urothelial Cancer Treatments (111 papers) and Urinary and Genital Oncology Studies (61 papers). Nicholas D. James collaborates with scholars based in United Kingdom, United States and Netherlands. Nicholas D. James's co-authors include Christine Théodore, Ronald de Wit, A Płużańska, Stéphane Oudard, Mario A. Eisenberger, Ian F. Tannock, Kim N., J Horti, Mark Rosenthal and Ingela Turesson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Genetics.

In The Last Decade

Nicholas D. James

320 papers receiving 13.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2004 4.3k citations Nicholas D. James et al. profile →
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

2012 617 citations Nicholas D. James, Syed A. Hussain et al. profile →
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

2000 442 citations Nicholas D. James et al. profile →

Peers

Countries citing papers authored by Nicholas D. James

Since Specialization

Citations

This map shows the geographic impact of Nicholas D. James's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas D. James with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas D. James more than expected).

Fields of papers citing papers by Nicholas D. James

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas D. James. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas D. James. The network helps show where Nicholas D. James may publish in the future.

Co-authorship network of co-authors of Nicholas D. James

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas D. James. A scholar is included among the top collaborators of Nicholas D. James based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas D. James. Nicholas D. James is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. 2025 ·Journal of Clinical Oncology ·Nicholas D. James, Hannah Rush, Matthew Nankivell, (unknown), Stephen Mangar, Neil McPhail, Simon J. Brown, Jacob Tanguay, Joanna Gale, Wael Mohamed, Simon J. Crabb, Omar Khan, John M. Russell, William Cross, Claire Murphy, (unknown), Noel W. Clarke, Mahesh Parmar, Duncan C. Gilbert, Ruth E. Langley	1
2	Management of Index Finger Metacarpophalangeal Joint Arthritis 2024 ·Orthopedic Clinics of North America ·(unknown), (unknown), (unknown), Nicholas D. James, (unknown), James H. Calandruccio	0
3	1656TiP The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT) 2024 ·Annals of Oncology ·Sarah Howlett, (unknown), Louise Brown, Claire Amos, Peter Dutey‐Magni, (unknown), Laura E. O’Shea, Catherine A. Hogan, Anna Wingate, (unknown), Rosalind A. Eeles, Michael Hubank, Phillip Williams, William Cross, (unknown), Nigel Clarke, (unknown), Nicholas D. James, Emily Grist, (unknown)	1
4	1657TiP The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT) 2024 ·Annals of Oncology ·Hassan Abdel‐Aty, Claire Amos, (unknown), (unknown), (unknown), Peter Dutey‐Magni, (unknown), Robert M. Bennett, (unknown), Ashutosh Sachdeva, (unknown), Laura Farrelly, David Matheson, (unknown), Patricia Díez, Olivia Naismith, (unknown), Gerhardt Attard, N. van As, Nicholas D. James	1
5	LBA70 Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE 2024 ·Annals of Oncology ·(unknown), (unknown), Nicholas D. James, Ashwin Sachdeva, G. Attard, (unknown), (unknown), Omar El‐Taji, M. Varughese, Joanna Gale, Simon J. Brown, Narayanan Srihari, (unknown), David Matheson, Claire Amos, Claire Murphy, Christine McAlpine, (unknown), Louise Brown, (unknown)	6
6	Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries 2024 ·JCO Global Oncology ·Fernando Sabino Marques Monteiro, (unknown), Denizar Vianna Araújo, Rana R. McKay, Karine Martins da Trindade, Andrey Soares, (unknown), (unknown), Diogo Assed Bastos, Nicholas D. James, Daniel Herchenhorn	0
7	Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT 2024 ·Health Technology Assessment ·Nicholas D. James, Sarah Pirrie, (unknown), James W.F. Catto, Kieran Jefferson, Prashant Patel, Ana Hughes, Ann Pope, Veronica Nanton, (unknown), (unknown), (unknown), Richard T. Bryan	1
8	1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT) 2024 ·Annals of Oncology ·(unknown), Hassan Abdel‐Aty, (unknown), (unknown), Peter Dutey‐Magni, (unknown), (unknown), Claire Amos, Iain Murray, (unknown), Nina Tunariu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Nicholas D. James	1
9	Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer 2023 ·European Urology Oncology ·Philip Sutera, Amol C. Shetty, Yang Song, (unknown), (unknown), Zaker Rana, Kenneth J. Pienta, Felix Y. Feng, Daniel Y. Song, Theodore L. DeWeese, Silke Gillessen, Christopher Sweeney, Nicholas D. James, Gerhardt Attard, Matthew P. Deek, Phuoc T. Tran	6
10	1782P Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1\|RT comparison 2023 ·Annals of Oncology ·(unknown), (unknown), Laura Murphy, Macey L. Murray, Louise Brown, Max Parmar, Nicholas D. James, Chris Parker, Matthew R. Sydes, Nigel Clarke, Ashwin Sachdeva	4
11	1767MO External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase III STAMPEDE trials 2023 ·Annals of Oncology ·Charles Parker, Larissa Mendes, Emily Grist, (unknown), D. van der Wal, John R. Griffin, Eric Chen, Phuoc T. Tran, Daniel E. Spratt, (unknown), (unknown), (unknown), (unknown), Matthew R. Sydes, Louise Brown, (unknown), Felix Y. Feng, Noel W. Clarke, Nicholas D. James, Gerhardt Attard	5
12	Identification of a Predictive Genomic Biomarker for Prostate Directed Therapy in Synchronous Low-Volume Metastatic Castration Sensitive Prostate Cancer 2023 ·International Journal of Radiation OncologyBiologyPhysics ·Philip Sutera, Amol C. Shetty, Yang Song, Tony N. Hodges, (unknown), (unknown), Kenneth J. Pienta, Felix Y. Feng, Daniel Y. Song, Theodore L. DeWeese, Silke Gillessen, Nicholas D. James, Gerhardt Attard, Matthew P. Deek, Phuoc T. Tran	0
13	Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer 2023 ·Clinical Oncology ·L. Philipps, Núria Porta, Nicholas D. James, Robert Huddart, (unknown), Leslie K. Ballas, Emma Hall	2
14	Boosting and broadening recruitment to UK cancer trials: towards a blueprint for action 2023 ·SHILAP Revista de lepidopterología ·Veronica Nanton, Richard T. Bryan, (unknown), Ana Hughes, Kieran Jefferson, (unknown), (unknown), (unknown), (unknown), Sarah Pirrie, (unknown), Annie Young, Prashant Patel, Nicholas D. James	3
15	1768MO Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: Analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons 2023 ·Annals of Oncology ·Craig Jones, Peter Dutey‐Magni, (unknown), (unknown), Janet E. Brown, Eugène McCloskey, Mahesh Parmar, Nicholas D. James, Matthew R. Sydes, Louise Brown, Noel W. Clarke, Ashwin Sachdeva	4
16	Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial 2022 ·White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·Syed A. Hussain, J.F. Lester, Richard A. Jackson, (unknown), (unknown), Anthony Elliott, Simon J. Crabb, Robert Huddart, Naveen Vasudev, Alison Birtle, Jane Worlding, Nicholas D. James, Omi Parikh, Maria Vilarino-Varela, Roberto Alonzi, Mark Linch, Irbaz Bin Riaz, James W.F. Catto, Thomas Powles, Robert J. Jones	20
17	The importance of lymph node location, burden and treatment outcome in M1 HSPC: analysis from the STAMPEDE trial arms A and C 2020 ·European Urology Open Science ·Áine Haran, (unknown), (unknown), Thomas Hambrock, Claire Amos, (unknown), Nicholas D. James, (unknown), Matthew R. Sydes, Noel W. Clarke	1
18	What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis 2018 ·Annals of Oncology ·Claire L. Vale, David J. Fisher, Ian R. White, James R. Carpenter, Sarah Burdett, Noel W. Clarke, Karim Fizazi, Gwénaëlle Gravis, Nicholas D. James, M.D. Mason, Mahesh Parmar, Larysa Rydzewska, Christopher J. Sweeney, Melissa Spears, Matthew R. Sydes, Jayne F. Tierney	52
19	Integrated Care in Prostate Cancer (ICARE-P): Nonrandomized Controlled Feasibility Study of Online Holistic Needs Assessment, Linking the Patient and the Health Care Team 2017 ·JMIR Research Protocols ·Veronica Nanton, Rebecca Appleton, Jeremy Dale, Julia Roscoe, Thomas Hamborg, Sam H. Ahmedzai, Theodoros N. Arvanitis, (unknown), Nicholas D. James, (unknown), Omar Khan, Deepak Parashar, Prashant Patel	8
20	Oral Presentations 7 2004 ·British Journal of Cancer ·Lyndon Gommersall, Farhat L. Khanim, D M Peehl, Alan Doherty, Nicholas D. James, Marion Campbell, Rakesh Heer, (unknown), Helen Robson, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact